Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486–97.
International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Available from: http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf (accessed 11 July 2009).
et al. Clinical and biochemical assessment of hypogonadism in men with Type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007; 30: 911–7. , ,
et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl. 2009; 30: 1–9. , ,
Insulin resistance, body fat distribution, and sex hormones in men. Diabetes. 1994; 43: 212–9. , , , .
et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab. 1997; 82: 682–5. , ,
Sex differences of endogenous sex hormones and risk of Type 2 diabetes. JAMA. 2006; 295: 1288–99. , , , .
Frequent occurrence of hypogonadotropic hypogonadism in Type 2 diabetes. J Clin Endocrinol Metab. 2004; 89: 5462–8. , , , , , .
et al. Endogenous sex hormones and the development of Type 2 diabetes in older men and women. Diabetes Care. 2002; 25: 55–60. , ,
et al. Testosterone, sex hormone binding globulin and the development of Type 2 diabetes in middle aged men. Diabetes Care. 2000; 23: 490–4. , ,
et al. Low levels of sex hormone binding globulin and testosterone predict the development of non insulin dependent diabetes mellitus in men. Am J Epidemiol. 1996; 143: 889–97. , ,
et al. Testosterone concentration in young patients with diabetes. Diabetes Care. 2008; 31: 2013–7. , ,
et al. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab. 1990; 71: 929–31. , ,
et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism. 1991; 40: 101–4. , ,
et al. Visceral fat accumulation in men is positively associated with insulin, glucose and C-peptide levels but negatively with testosterone levels. Metabolism. 1990; 39: 897–901. , ,
et al. Obesity, body fat distribution and sex hormones in men. Int J Obes. 1993; 17: 643–9. , ,
Relationship between serum sex hormones and the glucose–insulin–lipid defect in men with obesity. Metabolism. 1993; 42: 116–20. .
et al. Sex steroid hormones, upper body obesity and insulin resistance. J Clinl Endocrinol Metab. 2002; 87: 4522–7. , ,
Testosterone, body composition and aging. J Endocrinol Invest. 1999; 22: 110–6. , , .
et al. The effects of hypogonadism on body composition and bone mineral density in Type 2 diabetic patients. Diabetes Care. 2007; 30: 1860–1. , ,
The hypogonadal–obesity cycle. Med Hypotheses. 1999; 52: 49–51. .
et al. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology. 2003; 144: 5081–8. , ,
Testosterone associations with erectile dysfunction, diabetes and metabolic syndrome. Eur Urol Suppl. 2007; 6: 847–57. .
et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005; 90: 2636–41. , ,
et al. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000; 14: 1000–5. , ,
et al. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis. 2003; 166: 95–102. , ,
et al. Testosterone levels correlate positively with HDL cholesterol levels in men with Type 2 diabetes. Endocrine Abstr. 2007; 14: P628. , ,
et al. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø study. Eur J Endocrinol. 2004; 150: 65–71. , ,
Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertens. 1988; 6: 329–32. , .
et al. Disparate cardiovascular findings in men and women with essential hypertension. Ann Intern Med. 1987; 107: 158–61. , ,
Inverse correlation between testosterone and ventricle ejection fraction, hemodynamics and exercise capacity in heart failure patients with erectile dysfunction. Int Braz J Urol. 2008; 34: 302–10. , , .
The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis. 2009; 207: 318–27. , .
et al. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2007; 92: 4254–9. , ,
Androgens and body fat distribution. J Steroid Biochem Mol Biol. 2008; 108: 272–80. , , .
The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. Int J Obes Relat Metab Disord. 2000; 24(Suppl. 2): S59–63. .
et al. The effects of varying doses of testosterone on insulin sensitivity, plasma lipids, apolipoproteins and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 2002; 87: 136–43. , ,
et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care. 2005; 28: 1636–42. , ,
et al. Role of inflammatory mediators in the suppression of insulin receptor phosphorylation in circulating mononuclear cells of obese subjects. Diabetologia. 2007; 60: 278–85. , ,
et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle aged men: a meta-analysis. Clin Endocrinol. 2005; 63: 280–93. , ,
et al. Adverse effects of anabolic steroids in athletes. A constant threat. Toxicol Lett. 2005; 158: 167–75. , ,
Anabolic steroids. Baillieres Best Pract Res Clin Endocrinol Metab. 2000; 14: 55–69. , .
et al. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis. 1998; 41: 1–15. , ,
et al. Androgen treatment of abdominally obese men. Obes Res. 1993; 1: 245–51. , ,
Androgen supplementation in eugonadal men with osteoporosis effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone. 1996; 18: 171–7. , , .
Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab. 2007; 92: 3844–53. , .
et al. Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency. J Endocrinol. 2006; 189: 595–604. , ,
et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004; 89: 3313–8. , ,
et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004; 90: 871–6. , ,
et al. The effects of short term (3 weeks) testosterone treatment on serum inflammatory markers in men undergoing coronary artery stenting. Int J Cardiol. 2006; 109: 339–43. , ,
et al. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with Type 2 diabetes. Eur J Endocrinol. 2007; 156: 595–602. , ,
et al. Low testosterone and high C-reactive protein concentrations predict low haematocrit in Type 2 diabetes. Diabetes Care. 2006; 29: 2289–94. , ,
Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med. 2001; 111: 261–9. , , , .
Testosterone supplementation in men with Type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003; 6: 1–7. , , .
Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with Type 2 diabetes. Eur J Endocrinol. 2006; 154: 899–906. , , , .
52-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycaemic control in men with newly diagnosed Type 2 diabetes and subnormal plasma testosterone. J Androl. 2009; 30: 726–33. , , , .
Testosterone improves glycaemic control, insulin resistance, body fat and sexual function in men with metabolic syndrome and/or type 2 diabetes: a multicentre European clinical trial. The TIMES2 study. Endocrine Abstr. 2010; 21: OC1. , , .
Effect of testosterone on abdominal adipose tissue in men. Int J Obes. 1991; 15: 791–5. , , .
Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992; 75: 1092–8. .
Testosterone and regional fat distribution. Obes Res. 1995; 3(Suppl.): S609–12. .
et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999; 84: 2647–53. , ,
et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001; 56: M266–73. , ,
et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone. Diabetes Care. 2001; 24: 2149–51. , ,
et al. Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocr Pract. 2007; 13: 629–35. , ,
et al. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl. 2007; 53: 353–7. , ,
et al. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl. 2008; 29: 102–5. , ,
Impact of testosterone treatment on postprandial triglyceride metabolism in elderly men with subnormal testosterone levels. Scand J Clin Lab Invest. 2008; 11: 1–8. , , .
et al. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in non-obese aging men. J Clin Endocrinol Metab. 2008; 93: 139–46. , ,
et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. J Am Med Assoc. 1989; 261: 1165–8. , ,
et al. Metabolic and behavioral effects of high dose exogenous testosterone in healthy men. J Clin Endocrinol Metab. 1994; 79: 561–7. , ,
et al. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis. 1996; 121: 35–43. , ,
et al. Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. Jpn Heart J. 1997; 38: 73–82. , ,
et al. Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotropic hypogonadism. Horm Metab Res. 1998; 30: 642–5. , ,
et al. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol. 2001; 55: 315–24. , ,
et al. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab. 2001; 86: 4078–88. , ,